Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days
NCT01547169, Phase 2, Completed, University of Washington
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days | ClinicalTrials.gov |
| NCT number | NCT01547169 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Phase 2 | ClinicalTrials.gov |
| Enrollment | 60 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Washington | ClinicalTrials.gov |
| Conditions | Alzheimer's Disease, Mild Cognitive Impairment | ClinicalTrials.gov |
| Interventions | Placebo Comparator, insulin detemir, insulin detemir | ClinicalTrials.gov |
| First posted | 2012-03-07 | ClinicalTrials.gov |
| Last updated | 2012-12-18 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Verbal Memory Composite | Change from Baseline in Verbal Memory at 3 Weeks | The composite will consist of the weighted sum of Immediate + Delayed Story Recall and Immediate +Delayed List Recall | ClinicalTrials.gov |
| Secondary | Neuropsychological Test of Executive Function 1 | Change from Baseline in Executive Functioning at 3 Weeks | Computerized Dot Counting Test (test of executive functioning) | ClinicalTrials.gov |
| Secondary | Glucose Tolerance | Change from Baseline in Glucose Tolerance at 3 Weeks | Subjects will undergo oral glucose tolerance test (OGTT) to assess glucose tolerance | ClinicalTrials.gov |
| Secondary | Functional Ability | Change from Baseline in Functional Ability at 3 Weeks | Subjects will have a collateral informant (i.e., spouse or friend) rate the subjects' ability to carry out activities of daily living on the Dementia Severity Rating Scale. | ClinicalTrials.gov |
| Secondary | Plasma biomarkers of AD | Change from Baseline in Plasma Biomarkers at 3 Weeks | Plasma Abeta (ABeta 38, ABeta 40, and Abeta 42) and Tau (total tau and phosphorylated tau) will be measured in each subject. | ClinicalTrials.gov |
| Secondary | Neuropsychological Test of Executive Functioning 2 | Change from Baseline in Executive Functioning at 3 Weeks | Computerized Stroop Test | ClinicalTrials.gov |
| Secondary | Neuropsychological Tests of Visual Working Memory | Change from Baseline in Visual Working Memory at 3 Weeks | Benton Visual Retention Test Form F\&G (a test of visual working memory) | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|---|---|---|---|---|---|
| P50AG005136 | Alzheimer's Disease Research Center | GRABOWSKI, THOMAS J. | UNIVERSITY OF WASHINGTON | NATIONAL INSTITUTE ON AGING | 1985 to 2019 | NIH RePORTER |
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 2
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Short Story Recall | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Secondary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)